NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Doc logic, that is an excellent and important question.

Under normal circumstances, the UK regulatory environment encourages transparency, especially once a Marketing Authorisation Application is publicly known. However, there are indeed structured exceptions, and the current situation with NWBO and the murcidencel application fits within those boundaries.

During an active MAA review, the company is expected to maintain confidentiality until the Summary of Product Characteristics is finalized. That document defines the approved indication, dosing, manufacturing method, and safety language. Until it is locked, formal disclosure is not just discouraged, it can actually compromise the regulatory process. This is especially true if a variation has been submitted to adjust manufacturing or expand scope. Any public commentary before the variation is accepted could be considered improper influence or a breach of procedural confidentiality.

In addition, when a company like NWBO is also navigating overlapping legal exposure from market interference, and actively participating in Specials supply under Statutory Instrument Number 87, the margin for public comment narrows even further. Business and legal risk management naturally reinforce regulatory silence. The MHRA cannot publish approval decisions until all internal documentation is complete, and the company cannot issue statements until the MHRA grants formal consent or the SmPC is finalized.

So yes, both UK regulatory structure and NWBO’s current circumstances provide more than adequate justification for the current silence. The lack of public communication at this stage is both compliant and expected.

Best regards.